Enhancing therapeutic efficacy of photothermal therapy using poloxamer-reduced graphene oxide and mesenchymal stem cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jung Hwan | - |
dc.contributor.author | Yoon, Jeong-Kee | - |
dc.contributor.author | Kim, Yu-Jin | - |
dc.contributor.author | Lee, Tae-Jin | - |
dc.contributor.author | Jeong, Gun-Jae | - |
dc.contributor.author | Kim, Dong-Ik | - |
dc.contributor.author | Bhang, Suk Ho | - |
dc.date.accessioned | 2024-01-09T06:32:26Z | - |
dc.date.available | 2024-01-09T06:32:26Z | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 1226-086X | - |
dc.identifier.issn | 1876-794X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/70013 | - |
dc.description.abstract | Due to their heat-generating property based on exogenous energy irradiation, reduced graphene oxide particles (RGOs) have been widely used for photothermal cancer therapy. They show high absorbance for the near-infrared wavelength that is suitable for in vivo experimentation. However, enhancing the tumor-targeting efficiency and avoiding the self-aggregation of RGO to maximize the photothermal effect remain challenging. We demonstrated here that human mesenchymal stem cells (hMSCs) can deliver poloxamer conjugated RGOs (pRGOs) to target tumors. Self-aggregation limits cellular uptake and induces treatment of high particle concentrations for the photothermal effect. However, compared to RGOs, pRGOs did not show any self-aggregation. pRGOs-laden hMSCs injected intravenously to tumor-bearing mice led to significantly enhanced tumor-targeting efficiency and higher heat generation than injections of RGOs following exogenous laser irradiation. This work shows that the tumor tropism of hMSC can be applied for increased tumor-targeting efficiency with small amounts of particles. Taken together, the results indicate that combining hMSCs with pRGOs could increase the therapeutic effect in photothermal cancer therapy in a synergistic manner. (C) 2019 Published by Elsevier B.V. on behalf of The Korean Society of Industrial and Engineering Chemistry. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Enhancing therapeutic efficacy of photothermal therapy using poloxamer-reduced graphene oxide and mesenchymal stem cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jiec.2019.07.031 | - |
dc.identifier.bibliographicCitation | JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, v.80, pp 846 - 853 | - |
dc.identifier.kciid | ART002542463 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000501658800095 | - |
dc.identifier.scopusid | 2-s2.0-85074961873 | - |
dc.citation.endPage | 853 | - |
dc.citation.startPage | 846 | - |
dc.citation.title | JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY | - |
dc.citation.volume | 80 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Human mesenchymal stem cell | - |
dc.subject.keywordAuthor | Photothermal cancer therapy | - |
dc.subject.keywordAuthor | Poloxamer-reduced graphene oxide | - |
dc.subject.keywordPlus | GOLD NANOPARTICLES | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | POLYMER | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Engineering, Chemical | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.